Industry Partners

The ubiquitin pathway contains a plethora of novel therapeutic targets. Progenra's ability to discover novel structures with its high throughput assays has created several opportunities for establishing partnerships with other companies. 

Academic Partners

Recognizing that the power of its de-ubiquitylase and ligase technology program cannot be fully explored by the pharmaceutical industry alone, Progenra actively seeks academic laboratories that are keen to utilize Progenra technologies for investigating the functions of novel or known de-ubiquitylases and ligases.